Pharmacovigilance Market to Reach USD 22.8 Billion by 2036 as Rising Drug Safety Regulations and Clinical Trial Outsourcing Drive Global Growth

NEWARK, Del., Aug. 3, 2026 - The global Pharmacovigilance Market is poised for robust growth as pharmaceutical companies increasingly invest in comprehensive drug safety monitoring, adverse event reporting, and regulatory compliance throughout the product lifecycle. According to Future Market Insights (FMI), the market is projected to grow from USD 9.8 billion in 2026 to USD 22.8 billion by 2036, registering a 8.8% CAGR during the forecast period. Growing clinical trial activity, expanding regulatory requirements, rising outsourcing of pharmacovigilance services, and increasing adoption of AI-driven safety monitoring platforms continue driving global market expansion.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1107

The market is expected to create an absolute dollar opportunity of USD 13.0 billion between 2026 and 2036. Growth is supported by increasing global drug development activities, expanding post-marketing surveillance programs, and growing demand for technology-enabled pharmacovigilance solutions.

Key Pharmacovigilance Market Highlights at a Glance

· Market Size (2026): USD 9.8 Billion

· Forecast Market Size (2036): USD 22.8 Billion

· Forecast Period: 2026-2036

· CAGR (2026-2036): 8.8%

· Absolute Dollar Opportunity: USD 13.0 Billion

· Leading Type of Pharmacovigilance: Clinical Trial Pharmacovigilance (28.7% Market Share in 2026)

· Leading Phase: Clinical Phase (35.0% Market Share in 2026)

· Fastest-growing Country: China (8.9% CAGR through 2036)

· Key Segments Covered: Type of Pharmacovigilance, Phase, Drug Class, End User, Region

Analyst Viewpoint

"The pharmacovigilance market continues to evolve as pharmaceutical companies place greater emphasis on proactive drug safety management, regulatory compliance, and lifecycle risk assessment. Clinical trial pharmacovigilance remains central to market growth, while advances in artificial intelligence, automation, and real-world evidence are improving adverse event detection and operational efficiency across global pharmacovigilance programs."

Why Is the Pharmacovigilance Market Growing?

Growing regulatory scrutiny and increasing global drug development activities continue to drive demand for comprehensive pharmacovigilance services.

Key Growth Drivers

· Rising number of clinical trials worldwide.

· Increasing regulatory requirements for drug safety monitoring.

· Growing outsourcing of pharmacovigilance services.

· Expansion of post-marketing surveillance activities.

· Rising adoption of AI and automation in safety reporting.

· Increasing pharmaceutical R&D investments.

· Growing focus on patient safety and regulatory compliance.

As pharmaceutical companies continue expanding global clinical development programs, pharmacovigilance remains essential for ensuring drug safety and maintaining regulatory approval.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-1107

Which Type of Pharmacovigilance Leads the Market?

Clinical Trial Pharmacovigilance dominates the market, accounting for 28.7% of total revenue in 2026.

Growing clinical research activities, stricter regulatory requirements, and increasing complexity of multinational trials continue driving demand for comprehensive safety monitoring throughout clinical development.

Type Segment Highlights

· Clinical Trial Pharmacovigilance remains the leading service category.

· Global clinical research expansion supports demand.

· Regulatory compliance drives continuous investment.

· Outsourcing improves operational efficiency.

Why Does the Clinical Phase Dominate Pharmacovigilance Services?

The Clinical Phase accounts for 35.0% of the market in 2026, reflecting the importance of continuous safety monitoring during drug development.

Pharmaceutical companies increasingly invest in adverse event reporting, risk management, and regulatory documentation throughout all stages of clinical development.

Phase Highlights

· Clinical Phase remains the leading segment.

· Continuous safety monitoring supports regulatory approval.

· Increasing trial complexity expands service demand.

· Digital reporting platforms improve operational workflows.

👉 Explore the Latest Pharmaceutical Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/pharmaceuticals

How Are End Users Expanding Market Adoption?

Pharmaceutical and biotechnology companies remain the largest end users, while contract research organizations (CROs) continue expanding outsourced pharmacovigilance services through advanced digital safety platforms and global regulatory expertise.

End User Highlights

· Pharmaceutical companies remain primary buyers.

· CROs continue expanding pharmacovigilance outsourcing.

· Biotechnology companies increase safety monitoring investments.

· AI-enabled platforms improve reporting efficiency.

Market Dynamics

Market Drivers

Growing pharmaceutical R&D expenditure, increasing clinical trial activity, rising regulatory compliance requirements, expanding post-marketing surveillance, and rapid adoption of AI-enabled safety monitoring continue driving market growth.

Market Restraints

High implementation costs, evolving global regulatory frameworks, data privacy concerns, shortage of qualified pharmacovigilance professionals, and integration challenges across multiple reporting systems continue presenting barriers to market expansion.

Market Trends

Innovation continues reshaping the pharmacovigilance industry.

Major trends include:

· AI-powered adverse event detection.

· Automation of safety case processing.

· Expansion of pharmacovigilance outsourcing.

· Increased use of real-world evidence.

· Cloud-based drug safety platforms.

· Predictive safety analytics.

· Integration of regulatory technology (RegTech).

Regional and Country Outlook

China is projected to be the fastest-growing market, registering an 8.9% CAGR through 2036, supported by expanding pharmaceutical manufacturing, increasing clinical research activities, and wider adoption of volume-based procurement (VBP) initiatives.

India is expected to record a 7.9% CAGR, driven by expanding pharmaceutical outsourcing, growing clinical research capabilities, and increasing investments in healthcare infrastructure.

Germany and Brazil continue strengthening market demand through expanding pharmaceutical R&D investments, regulatory modernization, and increasing adoption of outsourced pharmacovigilance services.

Competitive Landscape

Competition remains focused on technology innovation, regulatory expertise, global service capabilities, AI-enabled pharmacovigilance platforms, and lifecycle safety management as leading companies strengthen their worldwide operations.

Key Companies

· IQVIA

· Parexel International Corporation

· Clario

· Pharmaceutical Product Development (PPD)

· IBM Corporation

👉 Read Full Report:
https://www.futuremarketinsights.com/reports/pharmacovigilance-market

Frequently Asked Questions

1. What is the projected size of the Pharmacovigilance Market by 2036?

The global Pharmacovigilance Market is projected to reach USD 22.8 billion by 2036, growing from USD 9.8 billion in 2026.

2. What is the expected CAGR of the Pharmacovigilance Market?

The market is forecast to expand at an 8.8% CAGR between 2026 and 2036.

3. Which type of pharmacovigilance dominates the market?

Clinical Trial Pharmacovigilance leads the market, accounting for 28.7% of total revenue in 2026.

4. Which phase holds the largest market share?

The Clinical Phase remains the leading segment with 35.0% of the global market in 2026.

5. What factors are driving market growth?

Growing clinical trial activity, increasing regulatory requirements, rising outsourcing of pharmacovigilance services, expanding post-marketing surveillance programs, and increasing adoption of AI-enabled drug safety platforms continue driving the global Pharmacovigilance Market.

Related Reports

· https://github.com/healthcarefarmaweb/blogs/wiki/Behavioral-Health-EMR-Market-Poised-to-Hit-USD-4.7-Billion-by-2036-Amid-Rising-Cloud%E2%80%90Based-Platform-Adoption

· https://github.com/healthcarefarmaweb/blogs/wiki/Global-Advanced-Endoscopic-Technologies-Market-to-Reach-USD-2.8-Billion-by-2036-as-AI-Imaging-and-Minimally-Invasive-Innovation-Accelerate-Demand

· https://github.com/healthcarefarmaweb/blogs/wiki/Hair-Growth-Oral-Strips-Market-to-Achieve-USD-772.5-Million-by-2036-Driven-by-Rising-Awareness-of-Hair-Health-and-Advanced-Oral-Strip-Technologies

Rahul Singh
AVP - Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales - sales@futuremarketinsights.com
For Media - Rahul.singh@futuremarketinsights.com
For Web - https://www.futuremarketinsights.com

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

This release was published on openPR.